Chronic Inducible Urticaria Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Celldex Therapeutics, Jasper Therapeutics

Chronic Inducible Urticaria Pipeline constitutes 4+ key companies continuously working towards developing 4+ Chronic Inducible Urticaria treatment therapies, analyzes DelveInsight.

Chronic Inducible Urticaria Overview:

Chronic Inducible Urticaria (CIndU) is a type of chronic urticaria where hives or wheals are triggered by specific physical or environmental factors, such as pressure, temperature changes, sunlight, or exercise. Unlike chronic spontaneous urticaria, which occurs without clear external triggers, CIndU symptoms are linked to identifiable stimuli. This condition can severely affect quality of life, requiring a comprehensive treatment approach.

CIndU's pathophysiology involves an overreaction of mast cells, which release histamine and other inflammatory mediators in response to triggers, causing symptoms like itching, redness, and swelling. Treatment typically includes antihistamines, leukotriene receptor antagonists, and, in severe cases, immunomodulatory agents.

Management focuses on avoiding known triggers and providing symptom relief, with patient education playing a critical role. Ongoing research is improving understanding and treatment, offering hope for better control of this condition.

Request for a detailed insights report on Chronic Inducible Urticaria pipeline insights @ https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Chronic Inducible Urticaria Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Inducible Urticaria Therapeutics Market.

Key Takeaways from the Chronic Inducible Urticaria Pipeline Report

DelveInsight's Chronic Inducible Urticaria pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Chronic Inducible Urticaria treatment.
In October 2024, Jasper Therapeutics reported preliminary results from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adults with cold urticaria (ColdU) or symptomatic dermographism (SD), two common subtypes of CIndU. Of the 15 participants enrolled, 14 (93%) showed a clinical response within 6 weeks. In the 120mg dose group, 10 out of 12 participants (83%) achieved a complete response, and 1 participant had a partial response. Briquilimab was well tolerated, with no serious adverse events or grade 3 or higher adverse events reported. Jasper has received regulatory approval to enroll a 180mg dose cohort in the study and plans to present full data in the first half of 2025.
In September 2024, Evommune announced the enrollment of the first patient in a Phase II trial of EVO756 for adults with CIndU.
In June 2024, Celldex Therapeutics revealed data showing that barzolvolimab significantly improves angioedema at 12 weeks in its Phase II clinical trial for chronic spontaneous urticaria (CSU).
In May 2024, Novartis shared new data confirming the long-term efficacy and safety of remibrutinib, a selective Bruton's tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU).
In March 2024, Jasper Therapeutics announced that the first patient had been dosed in its Phase Ib/IIa (SPOTLIGHT) clinical study of subcutaneous briquilimab for treating CIndU.
In February 2024, ARS Pharmaceuticals reported positive efficacy results from its Phase II inpatient chronic spontaneous urticaria study using neffy (epinephrine nasal spray), an investigational new drug.
Key Chronic Inducible Urticaria companies such as Celldex Therapeutics, Jasper Therapeutics, and others are evaluating new drugs for Chronic Inducible Urticaria to improve the treatment landscape.
Promising Chronic Inducible Urticaria pipeline therapies in various stages of development include Barzolvolimab, and others.

Chronic Inducible Urticaria Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Chronic Inducible Urticaria Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Inducible Urticaria treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Inducible Urticaria market.

Download our free sample page report on Chronic Inducible Urticaria pipeline insights @ https://www.delveinsight.com/sample-request/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Inducible Urticaria Emerging Drugs

Barzolvolimab: Celldex Therapeutics

Chronic Inducible Urticaria Companies

There are about four key companies developing therapies for Chronic Inducible Urticaria. Among them, Celldex Therapeutics has drug candidates for Chronic Inducible Urticaria in the most advanced stage, specifically Phase II.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Chronic Inducible Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Chronic Inducible Urticaria Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Chronic Inducible Urticaria Therapies and Key Companies: Chronic Inducible Urticaria Clinical Trials and advancements @ https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Inducible Urticaria Pipeline Therapeutic Assessment
• Chronic Inducible Urticaria Assessment by Product Type
• Chronic Inducible Urticaria By Stage
• Chronic Inducible Urticaria Assessment by Route of Administration
• Chronic Inducible Urticaria Assessment by Molecule Type

Download Chronic Inducible Urticaria Sample report to know in detail about the Chronic Inducible Urticaria treatment market @ Chronic Inducible Urticaria Therapeutic Assessment @ https://www.delveinsight.com/sample-request/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Chronic Inducible Urticaria Current Treatment Patterns
4. Chronic Inducible Urticaria - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chronic Inducible Urticaria Late-Stage Products (Phase-III)
7. Chronic Inducible Urticaria Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Inducible Urticaria Discontinued Products
13. Chronic Inducible Urticaria Product Profiles
14. Chronic Inducible Urticaria Key Companies
15. Chronic Inducible Urticaria Key Products
16. Dormant and Discontinued Products
17. Chronic Inducible Urticaria Unmet Needs
18. Chronic Inducible Urticaria Future Perspectives
19. Chronic Inducible Urticaria Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Chronic Inducible Urticaria Pipeline Reports Offerings: https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.